D'Argento Ettore, Rossi Sabrina, Schinzari Giovanni, Strippoli Antonia, Basso Michele, Cassano Alessandra, Barone Carlo
Department of Medical Oncology, Catholic University of Sacred Heart, Largo A. Gemelli, 8, 00168, Rome, Italy.
Department of Medical Oncology, Humanitas Clinical and Research Center, Via Manzoni, 56, 20089, Rozzano, MI, Italy.
Curr Treat Options Oncol. 2016 Dec;17(12):59. doi: 10.1007/s11864-016-0437-x.
New treatments-as immunotherapies and new antiangiogenic agents-are now available in second-line setting for patients affected by EGFR wild-type and ALK-negative non-small-cell lung cancer (NSCLC). Nintedanib, ramucirumab, nivolumab and pembrolizumab have to be included in the therapeutic sequences for patients affected by NSCLC, but no clear selection criteria are to date offered, except for patients with PD-L1 expression ≥50 %. Performance status, smoking habits and comorbidities should be considered as clinical criteria in order to select the appropriate treatment, but also tumour characteristics as histotype, platinum resistance and rapid progression after a first-line therapy should be taken into account. The aim of the present paper is to identify subgroups of patients eligible for different therapy sequences.
新的治疗方法，如免疫疗法和新型抗血管生成药物，目前可用于表皮生长因子受体（EGFR）野生型和间变性淋巴瘤激酶（ALK）阴性的非小细胞肺癌（NSCLC）患者的二线治疗。对于NSCLC患者，治疗方案中应包括尼达尼布、雷莫西尤单抗、纳武单抗和帕博利珠单抗，但迄今为止，除了程序性死亡受体配体1（PD-L1）表达≥50%的患者外，尚无明确的选择标准。为了选择合适的治疗方法，应将体能状态、吸烟习惯和合并症视为临床标准，但也应考虑肿瘤特征，如组织学类型、铂类耐药性以及一线治疗后的快速进展情况。本文的目的是确定适合不同治疗方案的患者亚组。
